Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPL409116 in Rheumatoid Arthritis
NCT05374785Phase 2Completed
- Sponsor
- Celon Pharma S.A.
- Start
- May 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of CPL409116 in rheumatoid arthritis (RA) (4 arms), sponsored by Celon Pharma S.A. Primary endpoint: Change in Disease Activity Score 28 joint count C reactive protein at 12 weeks. Started May 2022; status: completed.
02
Drugs
CPL409116
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05374785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05374785.